Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 18
2002 47
2003 89
2004 83
2005 106
2006 124
2007 170
2008 223
2009 292
2010 269
2011 290
2012 310
2013 286
2014 316
2015 339
2016 327
2017 306
2018 327
2019 282
2020 317
2021 308
2022 270
2023 250
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

4,706 results

Results by year

Filters applied: . Clear all
Page 1
Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia.
Lamb YN. Lamb YN. Am J Cardiovasc Drugs. 2020 Aug;20(4):381-392. doi: 10.1007/s40256-020-00421-1. Am J Cardiovasc Drugs. 2020. PMID: 32648167 Review.
In well-designed clinical trials evaluating the therapeutic efficacy of rosuvastatin/ezetimibe administered as either separate agents or as an FDC, rosuvastatin/ezetimibe was significantly more effective than rosuvastatin monotherapy (including at double the …
In well-designed clinical trials evaluating the therapeutic efficacy of rosuvastatin/ezetimibe administered as either separate agents …
Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
Hong SJ, Lee YJ, Lee SJ, Hong BK, Kang WC, Lee JY, Lee JB, Yang TH, Yoon J, Ahn CM, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK; LODESTAR Investigators. Hong SJ, et al. JAMA. 2023 Apr 4;329(13):1078-1087. doi: 10.1001/jama.2023.2487. JAMA. 2023. PMID: 36877807 Free PMC article. Clinical Trial.
INTERVENTIONS: Patients were randomly assigned to receive either the LDL-C target strategy, with an LDL-C level between 50 and 70 mg/dL as the target, or high-intensity statin treatment, which consisted of rosuvastatin, 20 mg, or atorvastatin, 40 mg. MAIN OUTCOMES AND MEAS …
INTERVENTIONS: Patients were randomly assigned to receive either the LDL-C target strategy, with an LDL-C level between 50 and 70 mg/dL as t …
Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.
Jin X, Kim MH, Han KH, Hong SJ, Ahn JC, Sung JH, Cho JM, Lee HC, Choi SY, Lee K, Kim WS, Rhee MY, Kim JH, Hong SP, Yoo BS, Cho EJ, Lee JH, Kim PJ, Park CG, Hyon MS, Shin JH, Lee SH, Sung KC, Hwang J, Kwon K, Chae IH, Seo JS, Kim H, Lee H, Cho Y, Kim HS. Jin X, et al. J Clin Hypertens (Greenwich). 2020 Oct;22(10):1835-1845. doi: 10.1111/jch.13893. Epub 2020 Sep 16. J Clin Hypertens (Greenwich). 2020. PMID: 32937023 Free PMC article. Clinical Trial.
We enrolled 202 patients who were randomly divided into the following three groups: telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg, telmisartan 80 mg + rosuvastatin 20 mg, and telmisartan/amlodipine 80/5 mg. ...The Least-Square (LS) mean (SE) for changes in MSS …
We enrolled 202 patients who were randomly divided into the following three groups: telmisartan/amlodipine 80/5 mg + rosuvastatin 20 …
Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights.
Chilbert MR, VanDuyn D, Salah S, Clark CM, Ma Q. Chilbert MR, et al. Drug Des Devel Ther. 2022 Jul 7;16:2177-2186. doi: 10.2147/DDDT.S332352. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35832642 Free PMC article. Review.
The recent approval of a combination tablet of high-intensity rosuvastatin and ezetimibe has introduced a potentially more beneficial option for cholesterol management in addition to the only available combination of moderate intensity simvastatin and ezetimibe. We aimed t …
The recent approval of a combination tablet of high-intensity rosuvastatin and ezetimibe has introduced a potentially more beneficial …
Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study.
Zheng H, Li H, Wang Y, Li Z, Hu B, Li X, Fu L, Hu H, Nie Z, Zhao B, Wei D, Karlson BW, Bots ML, Meng X, Chen Y, Wang Y; METEOR-China Investigators. Zheng H, et al. Stroke. 2022 Oct;53(10):3004-3013. doi: 10.1161/STROKEAHA.120.031877. Epub 2022 Aug 26. Stroke. 2022. PMID: 36017704 Free PMC article. Clinical Trial.
There were clinically relevant improvements in lipid parameters with rosuvastatin. We observed an adverse-event profile consistent with the known safety profile of rosuvastatin. CONCLUSIONS: Rosuvastatin 20 mg/d significantly reduced the progression of CIMT o …
There were clinically relevant improvements in lipid parameters with rosuvastatin. We observed an adverse-event profile consistent wi …
Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations.
Zhang L, Zhang S, Yu Y, Jiang H, Ge J. Zhang L, et al. Herz. 2020 Sep;45(6):594-602. doi: 10.1007/s00059-018-4767-2. Epub 2018 Nov 27. Herz. 2020. PMID: 30483816 English.
Both rosuvastatin and atorvastatin were well tolerated, with similar incidences of adverse events. CONCLUSION: Similar to the VOYAGER meta-analysis, which reported a greater efficacy of rosuvastatin in comparison with atorvastatin and simvastatin in Caucasian patien …
Both rosuvastatin and atorvastatin were well tolerated, with similar incidences of adverse events. CONCLUSION: Similar to the VOYAGER …
Effects of Fixed-dose Combination of Low-intensity Rosuvastatin and Ezetimibe Versus Moderate-intensity Rosuvastatin Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia: A Randomized, Double-blind, Multicenter, Phase III Study.
Lee SA, Kim W, Hong TJ, Ahn Y, Kim MH, Hong SJ, Kim BS, Kim SY, Chae IH, Kim BJ, Rhee MY, Shin JH, Kang TS, Cho JM, Kim JS, Lee CW. Lee SA, et al. Clin Ther. 2021 Sep;43(9):1573-1589. doi: 10.1016/j.clinthera.2021.07.016. Epub 2021 Aug 21. Clin Ther. 2021. PMID: 34429197 Free article. Clinical Trial.
PURPOSE: We investigated whether the combination therapy of low-intensity rosuvastatin and ezetimibe is an useful alternative to moderate-intensity rosuvastatin monotherapy in patients requiring cholesterol-lowering therapy. METHODS: This was a multicenter randomize …
PURPOSE: We investigated whether the combination therapy of low-intensity rosuvastatin and ezetimibe is an useful alternative to mode …
Rosuvastatin: Beyond the cholesterol-lowering effect.
Cortese F, Gesualdo M, Cortese A, Carbonara S, Devito F, Zito A, Ricci G, Scicchitano P, Ciccone MM. Cortese F, et al. Pharmacol Res. 2016 May;107:1-18. doi: 10.1016/j.phrs.2016.02.012. Epub 2016 Mar 2. Pharmacol Res. 2016. PMID: 26930419 Review.
Rosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis of cholesterol through competitively inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A reductase, a liver enzyme responsible of the rate-limiting step in cholesterol synthesi
Rosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis of cholesterol through competitively
Chinese yellow wine.
Hugenholtz PG. Hugenholtz PG. Acta Cardiol. 2016 Feb;71(1):1-2. doi: 10.2143/AC.71.1.3132090. Acta Cardiol. 2016. PMID: 26853246 No abstract available.
Rosuvastatin pharmacogenetics in African populations.
Soko ND, Masimirembwa C, Dandara C. Soko ND, et al. Pharmacogenomics. 2018 Dec;19(18):1373-1375. doi: 10.2217/pgs-2018-0168. Epub 2018 Nov 6. Pharmacogenomics. 2018. PMID: 30398065 Free article. No abstract available.
4,706 results